Skip to content
ABCLAbCellera Biologics Inc.

Earnings

When AbCellera Biologics Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 23, after the close

Tue, Feb 23, 2027in 97 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 18 – Mar 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$44.85M
Revenue, change from a year earlier: Q3 2026 +18.8%, Q2 2026 −76.3%, Q1 2026 +96.3%, Q4 2025 +788.4%
Net income
-$8.95M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$10.64M+18.8% vs Q3 2025

Latest results

  1. Q3 2026Nov 9, 2026, after the closeThe release0.1%by the close of Nov 10
    Revenue
    $10.64M
    +18.8%
    Net income
    -$40.76M
    N/M
    EPS
    -$0.13
    N/M
    Completed a $200 million offering of common shares and pre-funded warrants.
  2. Q2 2026Aug 5, 2026, after the closeThe release+10.3%by the close of Aug 6
    Revenue
    $4.05M
    −76.3%
    Net income
    -$55.43M
    N/M
    EPS
    -$0.18
    N/M
  3. Q1 2026May 11, 2026, after the closeThe release5.7%by the close of May 12
    Revenue
    $8.32M
    +96.3%
    Net income
    -$43.17M
    N/M
    EPS
    -$0.14
    N/M
  4. Q4 2025Feb 24, 2026, after the closeThe release0.9%by the close of Feb 25
    Revenue
    $44.85M
    +788.4%
    Net income
    -$8.95M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 9, 2026 · after-hoursNov 9, 202640 d10-Q$10.64M+18.8%-$0.130.1%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 5, 202636 d10-Q$4.05M−76.3%-$0.18+10.3%
Q1 2026Mar 31, 2026May 11, 2026 · after-hoursMay 11, 202641 d10-Q$8.32M+96.3%-$0.145.7%
FY 2025
Q4 2025derivedDec 31, 2025Feb 24, 2026 · after-hoursFeb 24, 202655 d10-K$44.85M+788.4%—0.9%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q$8.96M+37.6%-$0.1913.7%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q$17.08M+133.3%-$0.12+0.2%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 8, 202538 d10-Q$4.24M−57.5%-$0.15+1.0%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · after-hoursFeb 27, 202558 d10-K$5.05M−45.0%—11.3%
Q3 2024Sep 30, 2024Nov 4, 2024 · after-hoursNov 4, 202435 d10-Q$6.51M−1.4%-$0.175.9%
Q2 2024Jun 30, 2024Aug 6, 2024 · after-hoursAug 6, 202437 d10-Q$7.32M−27.2%-$0.1313.8%
Q1 2024Mar 31, 2024May 7, 2024 · after-hoursMay 7, 202437 d10-Q$9.95M−18.4%-$0.142.2%
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 9, 2026000059
10-QAug 5, 2026000046
10-QMay 11, 2026000028
10-KFeb 24, 2026000012
10-QNov 6, 2025000025
10-QAug 7, 2025000011
10-QMay 8, 2025023836
10-KFeb 27, 2025008689
10-QNov 4, 2024045026
10-QAug 6, 2024035248

Provenance

ProvenanceData status and checks

AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR